Chemotherapy-Induced Anemia

Mechanisms and Risk Factors

Chemotherapeutic agents directly impair hematopoiesis in the bone marrow, including synthesis of red blood cell precursors, according to the National Comprehensive Cancer Network 1
Nephrotoxic effects of certain agents can lead to decreased renal production of erythropoietin, as reported by the National Comprehensive Cancer Network 1
The myelosuppressive effects accumulate over repeated cycles of therapy, with anemia rates increasing from 19.5% in cycle 1 to 46.7% by cycle 5, as noted by the National Comprehensive Cancer Network 1
Cancer itself can contribute to anemia through inflammatory cytokines that lead to iron sequestration and decreased red blood cell production, according to the National Comprehensive Cancer Network 3
Platinum-based regimens are particularly associated with anemia due to combined bone marrow and kidney toxicity, as stated by the National Comprehensive Cancer Network 1
Patients with lung cancer and gynecologic malignancies have a high incidence of chemotherapy-induced anemia, as reported by the National Comprehensive Cancer Network 1
Multiple cycles of chemotherapy increase the risk of severe anemia, according to the National Comprehensive Cancer Network 1
Pre-existing renal disease is a risk factor for severe chemotherapy-induced anemia, as noted by Praxis Medical Insights 6

Anemia should be evaluated when hemoglobin levels fall below a certain threshold or decrease significantly from baseline, as recommended by the National Comprehensive Cancer Network 1
Common symptoms of anemia include fatigue, syncope, exercise dyspnea, headache, vertigo, and chest pain, as listed by the National Comprehensive Cancer Network 1
Initial assessment should include a complete blood count with indices and review of peripheral blood smear, as suggested by the National Comprehensive Cancer Network 4
Reticulocyte index helps distinguish between decreased production versus increased destruction/loss of red blood cells, according to the National Comprehensive Cancer Network 4
Iron studies should be performed to rule out absolute iron deficiency, as recommended by the National Comprehensive Cancer Network 5

Treatment decisions should consider the degree of anemia, presence of symptoms, and comorbidities, as stated by the National Comprehensive Cancer Network 4
For symptomatic patients or those with comorbidities, red blood cell transfusions should be considered, as recommended by the National Comprehensive Cancer Network 4
Intravenous iron supplementation may enhance response to erythropoiesis-stimulating agents in patients with functional iron deficiency, according to the National Comprehensive Cancer Network 5

Consider the nadir hemoglobin level when evaluating risk, as noted by the National Comprehensive Cancer Network 1